Search Results 871-880 of 18609 for Relapse
"Most patients who receive targeted immunotherapy will initially go into remission, but a significant fraction of patients will eventually relapse," Dr.
Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin lymphoma featured. Cancer. Mayo Clinic to offer CAR T-cell therapy for relapsed non-Hodgkin ...
... relapses, sex difference and imaging in MS. ... In a clinical trial setting, the research team also has shown that a poor recovery from the first presenting ...
The purpose of this study is to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory (R/R) MM.
The purpose of Phase I of this study is to evaluate the safety and tolerability of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia ( ...
... relapsed or refractory non-Hodgkin lymphoma), or uterus cancer. It is also used to treat rheumatoid arthritis, severe psoriasis (a skin disease), lupus ...
... relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma who have received at least 1 previous treatment.
... relapsed within 6 months, after first-line AML therapy. Outcomes for Hand and Foot Soft Tissue Sarcomas Treated with Limb Sparing Multimodal Therapy ...
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies ... relapse, and subsequent therapy. Effect of Agent Orange ...
The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.